BR0016918A - Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas - Google Patents
Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadasInfo
- Publication number
- BR0016918A BR0016918A BR0016918-8A BR0016918A BR0016918A BR 0016918 A BR0016918 A BR 0016918A BR 0016918 A BR0016918 A BR 0016918A BR 0016918 A BR0016918 A BR 0016918A
- Authority
- BR
- Brazil
- Prior art keywords
- antihypertensive
- melatonin
- patient
- treating
- resistance
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000003276 anti-hypertensive effect Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 3
- 229960003987 melatonin Drugs 0.000 abstract 3
- 239000002220 antihypertensive agent Substances 0.000 abstract 2
- 230000036772 blood pressure Effects 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2000/000009 WO2001049286A1 (en) | 2000-01-05 | 2000-01-05 | Method and formulation for treating resistance to antihypertensives and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0016918A true BR0016918A (pt) | 2004-03-23 |
Family
ID=11042938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0016918-8A BR0016918A (pt) | 2000-01-05 | 2000-01-05 | Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7332177B1 (https=) |
| EP (1) | EP1272177B1 (https=) |
| JP (1) | JP4996803B2 (https=) |
| CN (1) | CN1414851A (https=) |
| AT (1) | ATE359072T1 (https=) |
| AU (1) | AU782266B2 (https=) |
| BG (1) | BG65637B1 (https=) |
| BR (1) | BR0016918A (https=) |
| CA (1) | CA2396129C (https=) |
| CY (2) | CY1108018T1 (https=) |
| CZ (1) | CZ299931B6 (https=) |
| DE (1) | DE60034373T2 (https=) |
| DK (1) | DK1272177T3 (https=) |
| EA (1) | EA004679B1 (https=) |
| EE (1) | EE200200379A (https=) |
| ES (1) | ES2284471T3 (https=) |
| HK (1) | HK1052655A1 (https=) |
| HU (1) | HU227002B1 (https=) |
| IL (1) | IL150190A0 (https=) |
| IS (1) | IS6439A (https=) |
| MX (1) | MXPA02005783A (https=) |
| NO (1) | NO322567B1 (https=) |
| NZ (1) | NZ520078A (https=) |
| PL (1) | PL201219B1 (https=) |
| PT (1) | PT1272177E (https=) |
| SI (1) | SI1272177T1 (https=) |
| SK (1) | SK287508B6 (https=) |
| TR (1) | TR200201724T2 (https=) |
| TW (1) | TWI260983B (https=) |
| UA (1) | UA77394C2 (https=) |
| WO (1) | WO2001049286A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| US20050020666A1 (en) * | 2003-07-25 | 2005-01-27 | Dabur Research Foundation | Cardioprotective agents |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |
| KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
| US20130325151A1 (en) * | 2010-10-25 | 2013-12-05 | Uico, Llc | Control system with solid state touch sensor for complex surface geometry |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| WO2018033546A1 (en) * | 2016-08-18 | 2018-02-22 | Koninklijke Philips N.V. | Blood-pressure management |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| JP6830156B2 (ja) | 2016-10-31 | 2021-02-17 | ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． | メラトニンミニタブレットおよびその製造方法 |
| WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
| ES2724933A1 (es) * | 2018-03-13 | 2019-09-17 | Ocupharm Diagnostics Sl | Terapia combinada con melatonina para la reducción de la presión intraocular |
| GB2617102A (en) * | 2022-03-29 | 2023-10-04 | John Hemming Trading Ltd | Sleep therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2134789T3 (es) * | 1991-05-09 | 1999-10-16 | Neurim Pharma 1991 | Composiciones que contienen melatonina. |
| CA2116036A1 (en) * | 1991-10-18 | 1993-04-29 | F. Eugene Yates | Device for the transdermal administration of melatonin |
| US5646049A (en) * | 1992-03-27 | 1997-07-08 | Abbott Laboratories | Scheduling operation of an automated analytical system |
| DE69303919T2 (de) * | 1992-04-07 | 1997-01-30 | Neurim Pharma 1991 | Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie |
| EP0664339A4 (en) * | 1993-07-09 | 1999-04-28 | Wakunaga Seiyaku Kk | METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE. |
| MD1716C2 (ro) | 1995-02-01 | 2002-02-28 | Neurim Pharmaceuticals (1991) Ltd. | Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine |
| US5648727A (en) * | 1995-10-24 | 1997-07-15 | Dpc Cirrus Inc. | Capacitive level sensing pipette probe |
| US5700828A (en) | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
| AU2583397A (en) * | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
| RU2134108C1 (ru) | 1998-10-06 | 1999-08-10 | Заславская Рина Михайловна | Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии |
-
2000
- 2000-01-05 MX MXPA02005783A patent/MXPA02005783A/es active IP Right Grant
- 2000-01-05 JP JP2001549654A patent/JP4996803B2/ja not_active Expired - Lifetime
- 2000-01-05 SI SI200030958T patent/SI1272177T1/sl unknown
- 2000-01-05 AU AU18882/00A patent/AU782266B2/en not_active Expired
- 2000-01-05 CZ CZ20022346A patent/CZ299931B6/cs not_active IP Right Cessation
- 2000-01-05 TR TR2002/01724T patent/TR200201724T2/xx unknown
- 2000-01-05 BR BR0016918-8A patent/BR0016918A/pt not_active IP Right Cessation
- 2000-01-05 EP EP00900110A patent/EP1272177B1/en not_active Expired - Lifetime
- 2000-01-05 IL IL15019000A patent/IL150190A0/xx unknown
- 2000-01-05 SK SK973-2002A patent/SK287508B6/sk not_active IP Right Cessation
- 2000-01-05 HK HK03105037.1A patent/HK1052655A1/zh unknown
- 2000-01-05 PT PT00900110T patent/PT1272177E/pt unknown
- 2000-01-05 NZ NZ520078A patent/NZ520078A/en not_active IP Right Cessation
- 2000-01-05 US US10/169,467 patent/US7332177B1/en not_active Expired - Lifetime
- 2000-01-05 WO PCT/IL2000/000009 patent/WO2001049286A1/en not_active Ceased
- 2000-01-05 DE DE60034373T patent/DE60034373T2/de not_active Expired - Lifetime
- 2000-01-05 HU HU0204089A patent/HU227002B1/hu unknown
- 2000-01-05 EA EA200200738A patent/EA004679B1/ru not_active IP Right Cessation
- 2000-01-05 EE EEP200200379A patent/EE200200379A/xx unknown
- 2000-01-05 AT AT00900110T patent/ATE359072T1/de active
- 2000-01-05 CA CA2396129A patent/CA2396129C/en not_active Expired - Lifetime
- 2000-01-05 DK DK00900110T patent/DK1272177T3/da active
- 2000-01-05 CN CN00818153A patent/CN1414851A/zh active Pending
- 2000-01-05 ES ES00900110T patent/ES2284471T3/es not_active Expired - Lifetime
- 2000-01-05 PL PL356325A patent/PL201219B1/pl unknown
- 2000-05-01 UA UA2002076326A patent/UA77394C2/uk unknown
-
2001
- 2001-07-10 TW TW090116904A patent/TWI260983B/zh not_active IP Right Cessation
-
2002
- 2002-06-24 IS IS6439A patent/IS6439A/is unknown
- 2002-06-27 NO NO20023102A patent/NO322567B1/no not_active IP Right Cessation
- 2002-08-05 BG BG106978A patent/BG65637B1/bg unknown
-
2007
- 2007-07-10 CY CY20071100916T patent/CY1108018T1/el unknown
- 2007-12-04 US US11/950,039 patent/US8075914B2/en not_active Expired - Fee Related
- 2007-12-18 CY CY200700033C patent/CY2007033I1/el unknown
-
2011
- 2011-10-25 US US13/281,212 patent/US8728511B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0016918A (pt) | Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| BR0113447A (pt) | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica | |
| TW200607510A (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| ATE241378T1 (de) | Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
| BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
| NZ520083A (en) | The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure | |
| PL349335A1 (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
| BR0115208A (pt) | Tratamento aperfeiçoado | |
| BR0014262A (pt) | Preparação antioxidante com base em extratos vegetais para o tratamento de problemas de adiposidade e circulatórios | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| BR0114759A (pt) | Utilização de inibidores da apoptose dos perìcitomas para o tratamento e/ou a prevenção da retinopatia diabética | |
| DE69930271D1 (de) | Medizinische zusammensetzungen zur behandlung von augenerkrankungen | |
| BR0010515A (pt) | Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica | |
| BR0015149A (pt) | Método e composições para administração de taxanos oralmente a pacientes humanos | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| BR9813549A (pt) | Processo para prevenção e tratamento de miocárdio afetado por lesão | |
| BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| BR0211855A (pt) | Medicamento e método para tratamento e melhoria da qualidade restauradora do sono | |
| BRPI0411237A (pt) | método para tratamento da esquizofrenia, e, usos de um agente antipsicótico, e de asenapina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8AE 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |